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Abstract
Endothelin-1 (ET-1) is a putative messenger of oxygen in the ductus arteriosus. Since the ability of the vessel to
contract to oxygen increases with gestation, we wished to ascertain whether ET-1 action is also developmentally
regulated. A corollary objective was to assess whether any gestational variation in the ET-1 contraction is due to a
change in the ETA-mediated action or to a shift in the balance between opposing, contractile (ETA - mediated) and
relaxant (ETB-mediated), actions. Experiments were performed with isolated ductal strips from preterm (0.7
gestation) and near-term fetal lambs. ET-1 contracted the ductus dose-dependently (1010–107 M) at both ages;
however, the peak contraction was about double in magnitude at term. Regardless of age, ET-1 contraction was
greater with preparations kept in the dark compared to those exposed to light. This effect of light was not seen after
removing the endothelium or when treating the intact tissue with the ETB antagonist BQ788 (1 AM). In the dark,
however, BQ788 did not modify significantly the ET-1 response at either age. We conclude that ET-1 becomes a
stronger ductus constrictor with fetal age, conceivably by acting on ETA receptors. Hence, the concept of ET-1
mediating the oxygen contraction is further validated. Peculiarly, the ET-1 contraction is curtailed by light through
a hitherto undefined ETB receptor-linked process. D 2002 Elsevier Science Inc. All rights reserved.
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Introduction
The ductus arteriosus is a special fetal shunt, connecting the pulmonary artery with the aorta and
allowing blood to bypass the high-resistance vascular bed within the unexpanded lungs. After birth,
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the ductus closes coincidentally with the onset of lung ventilation and the attendant fall in pulmonary
vascular resistance. Prostaglandin(PG) E2 is primarily responsible for patency of the vessel in the
fetus, while the rise in blood oxygen tension, marking the transition from intra- to extrauterine life, is
viewed as a trigger for the constriction leading to closure [1–3]. Indeed, failure of the ductus to close,
as often happens in the preterm newborn, is ascribed to the combination of two factors, the impact of
relaxing mechanism(s) becoming operational early in gestation and the poor susceptibility to oxygen
[1–3].
Several findings implicate endothelin-1 (ET-1) as a messenger in the constriction of the ductus to
oxygen and, by extension, assign to the action of this peptide, in conjuction with the waning action of
PGE2 at birth, a role in the process of closure [4–8]. ET-1, acting via the ETA receptor subtype, is a
singularly potent ductus constrictor. The peptide is also formed in the vessel wall, both within and
without the endothelium, and its formation correlates positively with the oxygen tension. Interference
with ET-1 synthesis or action, whether achieved pharmacologically or through genetic manipulation,
curtails the oxygen effect. On the other hand, results with an ETA antagonist reportedly arguing against
this concept [9] have been linked to a methodological problem [5]. All these data, however, have been
obtained in the ductus from perinatal animals and, consequently, no information is available on the
development of the ET-1-based mechanism vis-a-vis the increasing effectiveness of oxygen with
gestation.
The purpose of our investigation was to ascertain whether, in accord with its postulated messenger
function, ET-1 is a less effective constrictor on the preterm than the term ductus. A corollary aim was to
examine whether any reduction in the ETA-mediated constrictor response is coupled with an enhance-
ment of the ETB-mediated relaxant response. Theoretically, in the premature ETB receptors could
override ETA receptors as a target for ET-1 being formed in response to oxygen. The existence in the
vessel of a functional ETB receptor is supported by the observation, made at term, that ET-1 action
conceals a relaxant component within the overriding contraction [5,10] and that oxygen, hence by
inference ET-1, may exert a relaxant rather than a contractile effect when the ETA receptor is absent [5].
In the course of the investigation it was also realized that ET-1 action on the isolated ductus is modified
by ambient illumination. This peculiar phenomenon had not been recognized in the past, and results
obtained in the absence and presence of an overhead fluorescent lighting were pooled [10]. The latter
observation entailed a re-evaluation of our previous study [10] and separate experiments in the light and
the dark.
Methods
Experiments were performed on preterm (103–107 days, 0.7 gestation) and near-term (133–139 days
gestation; term, 145 days) pregnant sheep. Animals were mostly Southdown-Dorset crossbred, with
Targhee and Suffolk-Finnish Landrace crossbred making the balance. Surgical procedures and
experimental protocols were approved by the Animal Care Committee of our institution.
Solutions and drugs
The Krebs solution had the following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, KH2PO4 1,
MgSO4 0.9, dextrose 11.1 and NaHCO3 25. Potassium-Krebs solution (55 mM) was prepared by
F. Coceani et al. / Life Sciences 71 (2002) 1209–12171210
substituting NaCl with an equimolar amount of KCl. Solutions were bubbled with gas mixtures
containing either no O2 or O2 at 2.5% plus 5% CO2 in N2. Po2 was measured with an Instrumentation
Laboratory gas analyzer (model 1610, Lexington, MA) and was, respectively, 9.8 F 0.3 and 18.8 F 0.5
mmHg (pH 7.403 F 0.004). ET-1 (human and porcine type; Peninsula, Belmont, CA) was dissolved
under aseptic conditions in sterile water containing 0.05% human serum albumin. Aliquots of this stock
solution (0.25 mg/ml) were stored at 20 jC and, on the day of the experiment, were diluted with
bovine serum albumin (BSA)-supplemented saline. BQ123 and BQ788, which are selective antagonists
for, respectively, the ETA [11] and ETB [12] subtype of the endothelin receptor (both courtesy of Merck
Frosst, Montreal, Canada), were dissolved directly in saline. Doses of all compounds are given in molar
concentrations and refer to their final concentration in the bath. Vehicle alone, without or with BSA
(0.05%), had no effect on vessel tone.
Experimental procedure
Anesthesia, cesarean delivery of fetuses, and isolation of the ductus arteriosus have been
described in detail [13]. Throughout the procedure, care was taken not to expose the ductus to
ambient air, and ice-cold Krebs solution gassed with the zero O2 mixture was used for transportation
and dissection.
As previously reported [13], the ductus arteriosus was opened and then cut perpendicularly to the
main axis to yield one or two strips, depending on the age of the fetus and the attendant length of the
vessel. Ductal strips were used intact or after removing the endothelium by rubbing filter paper
(Whatman no. 41) over the intimal surface. Complete removal was confirmed in certain experiments by
scanning electron microscopy [14]. Preparations were mounted in individual 10-ml baths between a
stationary glass rod and an isometric tension transducer (Grass FT-03C) coupled to a Grass polygraph.
The initial load was applied in a single step (term ductus, 1.53 F 0.007 g; 1 g weight = 9.8 mN) or a
series of steps (preterm ductus, 1.5 F 0.008 g), and preparations were stretched by about 50% of the
original length to obtain an optimal tension output [15]. Precautions were used at each step not to
damage the endothelium when handling preparations of the whole ductus.
Tissues were equilibrated in Krebs solution gassed with the 2.5% O2 mixture, and the same gas
mixture was employed in the actual experiments to mimic the condition in utero [13]. Depending on the
protocol, the room was either illuminated with fluorescent lamps located in the ceiling or was kept
darkened.
The study included several protocols, but only one protocol was used with each vessel. In addition, to
avoid possible interference from tachyphylaxis, ET-1 was tested once, and any change in its effect due to
the ETA antagonist (BQ123), the ETB antagonist (BQ788), or room illumination was ascertained by
comparing results in different vessels. In protocol 1, ET-1 was tested on the intact, untreated ductus from
term and preterm animals. The peptide was added to the organ bath in cumulative doses (1 pM–0.1 AM),
using 3- to 10-fold increments. Separate tests were done in the light and the dark. An equivalent
experiment was carried out in protocol 2, using endothelium-denuded term preparations. In certain cases,
BQ123 (1 AM) was included in the medium 60 min prior to the ET-1 test to ascertain whether contractile
responses are ETA-mediated or result in part from activation of a subset of the ETB receptors (i.e. ETB2)
[16]. In protocol 3, intact vessels (preterm and term) were tested with ET-1 after a 60-min pretreatment
with BQ788 (1 AM), both in the absence and presence of light. The same protocol was used with few
endothelium-denuded, term preparations.
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Analysis of data
Baseline contractile tension, which varied with the preparation (see Results), refers to the net active
tension (i.e. total tension minus applied tension) developed by the preparation prior to any treatment.
Responses to ET-1 and excess potassium are given as the fractional change from baseline.
Data are expressed as the mean F s.e. mean. Statistical comparison of two means was done by
Student’s t test for unpaired observations. Multiple comparisons were made with a two-way repeated
measures analysis of variance (ANOVA) followed by an F-test for simple effect. Differences are
considered significant for p V 0.05.
Results
In agreement with previous work [13], intact ductal strips developed intrinsic tone during the initial
period of equilibration, with tension values progressing first to a peak and then abating to a stable level.
The ensuing baseline tone was higher for term than preterm preparations, but no obvious difference
could be detected at either age depending on room illumination (Table 1). A similar contractile pattern
was noted with term preparations lacking the endothelium, though their final tension output appeared to
be greater in the dark (Table 1). Excess potassium elicited a stronger contraction in the term than the
preterm ductus and, in the former case, its magnitude was slightly greater in the dark (Table 1).
Effect of ET-1
ET-1 contracted the intact ductus dose-dependently over the range between 1010 and 107 M (Figs. 1
and 2) and, in accord with previous results at term [10], this contraction was slow in development. While
threshold concentration did not differ between the two fetal ages examined, peak contraction was about
double in magnitude at term (compare Figs. 1 and 2). In comparison, the average response to excess
potassium increased at most 65% over the same gestation period (Table 1). Regardless of age, however,
the peptide proved to be more effective when preparations were kept in the dark compared to those
exposed to light (Figs. 1 and 2). Conversely, no such change in ET-1 action depending on room
Table 1
Contractile tension of term and preterm (0.7 gestation) ductus arteriosus
Preparation Steady-state tension Potassium contraction
dark light dark light
intact ductus, term 0.75 F 0.23 (14) 0.68 F 0.17 (20) 6.5 F 0.3 (10) 5.4 F 0.3 (15)*
endothelium-denuded
ductus, term
1.14 F 0.47 (5) 0.38 F 0.07 (17)* – 6.2 F 0.6 (4)
intact ductus, preterm 0.33 F 0.09 (13) 0.2 F 0.07 (12)+ 3.9 F 0.3 (9)++ 4.1 F 0.4 (6)+
Values (g) are mean F s.e. mean for the number of experiments given in parentheses. Note that values of steady-state tension
(i.e. baseline tension) refer to the entire tension developed by the preparation (i.e. total tension minus applied tension), while
responses to excess potassium are expressed as the increase of tension over baseline. *vs. preparation kept in the dark at the
same age, p < 0.05 (Student’s t test). + vs. term preparation kept in the light, p < 0.05 (Student’s t test). ++ vs. term preparation
kept in the dark, p < 0.001 (Student’s t test).
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Fig. 2. Intact strip of ductus arteriosus from preterm (0.7 gestation) fetal lamb. Concentration-response curves to ET-1 before
(dark, n = 8; light, n = 6) and during (dark, n = 5; light, n = 6) treatment with BQ788 (1 AM). Note the different scale on the
ordinate compared to Fig. 1. *vs. control in the dark, p = 0.05 (ANOVA). +vs. BQ788 treatment in the light, p < 0.05 (ANOVA).
Fig. 1. Intact strip of ductus arteriosus from near-term fetal lamb. Concentration-response curves to ET-1 before (dark, n = 9;
light, n = 15) and during (dark, n = 5; light n = 5) treatment with BQ788 (1 AM). Note that the control curve in the light includes
experiments from a previous series [10] (i.e. 14 of the original 16 experiments) where results were pooled regardless of room
lighting. When necessary, in this and the following figures points have been offset to improve visibility. *vs. control in the dark,
p < 0.01 (ANOVA). +vs. BQ788 treatment in the light, p < 0.01 (ANOVA).
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illumination was noted, at least at term, after preparations had been freed of their endothelium (Fig. 3). In
fact, there was no significant difference in responsiveness to ET-1 between the intact ductus being kept
in the dark and the endothelium-denuded ductus exposed to light.
Effect of BQ788 and BQ123 on the ET-1 response
At both ages, any reduction in the ET-1 contraction due to light disappeared after adding BQ788
to the perfusion fluid, while the same treatment was without a significant effect in the dark (Figs. 1
and 2). Hence, response curves of BQ788-treated tissues to ET-1 overlapped over the entire dose-
range (Figs. 1 and 2). Conversely, BQ788 did not cause any appreciable change in the contraction to
excess potassium (4.7 and 4.4 g, respectively, before and after BQ788 in the light; n = 2 for each
group). Regardless of room illumination, BQ788-treated tissues still responded unequally to ET-1
depending on fetal age and, in that respect, did not differ from the untreated tissues (compare Figs.
1 and 2).
BQ123 curtailed the contraction of the endothelium-denuded ductus to ET-1, thus causing a rightward
shift in the dose-response curve (Fig. 3). Under the same condition, BQ788 has instead no significant
effect (Fig. 3).
Discussion
The present study demonstrates that ET-1 mimics oxygen in becoming a more effective ductus
constrictor with the progress of gestation. This developmental change is not caused by a relatively
greater influence of ETB receptors causing relaxation in the premature, but results instead from a varying
Fig. 3. Endothelium-denuded strips from near-term fetal lamb. Concentration-response curves to ET-1 before (dark, n = 5; light,
n = 6) and during treatment with BQ788 (1 AM) (n = 5) or BQ123 (1 AM) (n = 6). *vs. control in the light, p < 0.01 (ANOVA).
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response to ETA receptor activation. Maturation of the contractile apparatus, on the other hand, could
account only in part for our finding, because the potassium contraction is less affected than the ET-1
contraction by prematurity. Hence, the coincidence of effects between ET-1 and oxygen further validates
the concept [4–8] of an oxygen messenger function for ET-1.
While the acquisition of new evidence in support of this mediator role for ET-1 is a significant result,
the attenuation of ET-1 action by light is peculiar and warrants discussion. An unspecific effect of the
light on muscle tone [17], making the vessel less responsive to ET-1, is unlikely. Photoinduced
relaxation occurs in the ductus [18,19], as in other blood vessels [17], but in our experience this effect is
small and generally short-lived. In fact, the relatively minor impact of light on ductal muscle is also
evident here from the tension measurements made at rest and during treatment with excess potassium
(see Table 1). Equally unfeasible, with the concentrations being used, is a structural modification of ET-1
by free radicals [20] generated upon exposure to light. The finding instead that light-induced reduction in
the ET-1 contraction subsides after removing the endothelium or upon treating the tissue with BQ788
points to a selective involvement of the ETB receptors. Supporting our conclusion is also the lack of any
light-induced change of ET-1 action in the endothelium-denuded ductus, hence in a preparation where
only ETA receptors appear to be functional. The actual mechanism by which light alters ETB receptors
and related messenger systems (eg. NO/endothelial NO synthase; prostanoid/cyclooxygenase-2) [21,22]
remains speculative. A possibility, based on available data [23], is that light hinders the sequestration of
NO into nitrosothiols, thus leading to a larger pool of free NO upon ETB activation. NO is a natural
relaxant in the ductus of several species, including the lamb [24–26]. Any excess NO could, in turn,
oppose the ET-1 contraction by exerting a direct relaxation or by interfering with the binding of the
peptide to its ETA target [27]. Clearly, the two actions are not mutually exclusive and may well develop
synergistically.
Regardless of whether or not NO is involved in this effect of light, our observation may have practical
implications and may, in particular, explain the impact of ambient illumination on the development of a
persistent ductus in prematurely born infants [28]. By extension, it also raises the prospect in such
patients of employing an ETB antagonist as an adjuvant to the conventionally administered cyclo-
oxygenase inhibitor [29,30].
In summary, our study demonstrates that, in constricting the ductus arteriosus, ET-1 shares with
oxygen the increasing effectiveness with advancing gestation. This coincidence between the two agents
is consistent with the concept of ET-1 being a messenger for oxygen. Peculiarly, the magnitude of the
ET-1 contraction is curtailed by ambient light through a hitherto undefined ETB receptor-linked
mechanism. It remains to be ascertained whether the latter phenomenon is specific for the ductus or
extends to other blood vessels in the fetus and the adult.
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